Trinidad M. V.
- Country
- Spain
- Department
- Dermatology Department
Research Overview
- Evaluation of Long-Term Safety, Tolerability, and Efficacy of Subcutaneous Amlitelimab in Patients with Moderate to Severe Atopic Dermatitis from Previous Trials
- Phase II Evaluation of Autologous Skin-Derived Keratinocytes and Fibroblasts in Fibrin Matrix for Reconstructive Surgery in Basal Cell Carcinoma
- Evaluation of Amlitelimab Monotherapy in Maintaining Treatment Response in Adolescents and Adults with Moderate-to-Severe Atopic Dermatitis
Data & Insights
Has run more than one trial at 114 of 221 partner sites.
Specializations
Dermatological Research
The investigator specializes in treating moderate-to-severe atopic dermatitis, with particular emphasis on innovative therapeutic approaches and long-term disease management strategies.
- Novel Biologic Therapies
- Chronic Skin Conditions
- Adolescent and Adult Treatment Protocols
Their work encompasses evaluation of sustained clinical responses and treatment maintenance in dermatological conditions.
Skin Cancer Treatment
The investigator focuses on advanced treatments for basal cell carcinoma, particularly investigating reconstructive surgical approaches and innovative skin replacement technologies.
- Reconstructive Surgery Techniques
- Artificial Skin Development
- Tissue Engineering
Their research includes evaluation of nanostructured autologous skin treatments and surgical wound healing processes.
Therapeutic Innovation
The investigator explores monotherapy treatments and novel biological agents for chronic skin conditions, with specific attention to long-term efficacy and safety profiles.
- Immunological Treatments
- Long-term Safety Evaluation
- Treatment Response Assessment
Their expertise extends to developing maintenance therapy protocols and evaluating treatment withdrawal effects.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.